DelveInsight’s, “Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Anaplastic Lymphoma Kinase (ALK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Overview
The anaplastic lymphoma kinase (ALK) receptor is a membrane-bound tyrosine kinase. The pathogenesis of several cancers is closely related to aberrant forms of ALK or aberrant ALK expression, including ALK fusion proteins, ALK-activated point mutations, and ALK amplification. Clinical applications of different ALK inhibitors represent significant progress in targeted therapy.
Function - The receptor ALK plays a pivotal role in cellular communication and in the normal development and function of the nervous system. This observation is based on the extensive expression of ALK messenger RNA (mRNA) throughout the nervous system during mouse embryogenesis. In vitro functional studies have demonstrated that ALK activation promotes neuronal differentiation of PC12 or neuroblastoma cell lines.
Anaplastic Lymphoma Kinase (ALK) Inhibitors - ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it. A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion.
The companies and academics are working to assess challenges and seek opportunities that could influence Anaplastic Lymphoma Kinase (ALK) Inhibitors R&D. The therapies under development are focused on novel approaches for Anaplastic Lymphoma Kinase (ALK) Inhibitors.
This segment of the Anaplastic Lymphoma Kinase (ALK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anaplastic Lymphoma Kinase (ALK) Inhibitors Emerging Drugs
Ensartinib: Betta Pharmaceuticals
Ensartinib hydrochloride is a potent and highly selective next-generation ALK inhibitor with independent intellectual property rights, and it is developed jointly by Betta Pharmaceuticals Co., Ltd. and its subsidiary Xcovey Holding, Inc. (Xcovery). Ensartinib hydrochloride is another product following the EGFR-TKI in Betta’s lung cancer pipeline, and it is expected to be the first innovative targeted drug for lung cancer which is launched globally by a Chinese company. Currently, it is in phase 3 stage of development for the treatment of Non-small cell lung cancer.
TPX 0131: Turning Point Therapeutics
TPX-0131 is a next-generation ALK inhibitor entering IND-enabling studies. It has been designed with a novel compact macrocyclic structure and has shown preclinical potent inhibition of wildtype and numerous ALK mutations, including the clinically observed G1202R solvent-front mutation and the G1202R/L1196M compound mutation. Currently, it is in phase ½ of development stage for the treatment of Non-small cell lung cancer.
Further product details are provided in the report……..
This segment of the report provides insights about the different Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the Anaplastic Lymphoma Kinase (ALK) Inhibitors. The companies which have their Anaplastic Lymphoma Kinase (ALK) Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Betta Pharmaceuticals.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Anaplastic Lymphoma Kinase (ALK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anaplastic Lymphoma Kinase (ALK) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Anaplastic Lymphoma Kinase (ALK) Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anaplastic Lymphoma Kinase (ALK) Inhibitors Collaboration Deals
Late Stage Products (Phase III)
Ensartinib: Betta Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
TPX 0131: Turning Point Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
BI-1701963: Boehringer Ingelheim
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
MRTX-1133: Mirati Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Anaplastic Lymphoma Kinase (ALK) Inhibitors Key Companies
Anaplastic Lymphoma Kinase (ALK) Inhibitors Key Products
Anaplastic Lymphoma Kinase (ALK) Inhibitors- Unmet Needs
Anaplastic Lymphoma Kinase (ALK) Inhibitors- Market Drivers and Barriers
Anaplastic Lymphoma Kinase (ALK) Inhibitors- Future Perspectives and Conclusion
Anaplastic Lymphoma Kinase (ALK) Inhibitors Analyst Views
Anaplastic Lymphoma Kinase (ALK) Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Anaplastic Lymphoma Kinase (ALK) Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Anaplastic Lymphoma Kinase (ALK) Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Betta Pharmaceuticals
• Turning Point Therapeutics
• Nuvalent
• Roche
• LegoChem Biosciences
• Pfizer
• Qilu Pharmaceutical
• Ascentage Pharma
• Suzhou Zelgen Biopharmaceuticals
• Chia Tai Tianqing Pharmaceutical Group
• Beijing Pearl Biotechnology
• Novartis
